Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?

Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?

Standard curative treatment of early-stage non-small cell lung cancer (NSCLC) involves surgery in combination with postoperative (adjuvant) platinum-based chemotherapy where indicated. Preoperative (neoadjuvant) therapies offer certain theoretical benefits compared with adjuvant approaches, includin...

Full description

Bibliographic Details
Main Authors: Nick Pavlakis, Ken O'Byrne, Elizabeth Ahern, Brett G M Hughes, Ben J Solomon, Rina Hui
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/6/e002248.full

Internet

https://jitc.bmj.com/content/9/6/e002248.full

Similar Items